



# Oligodendroglioma workshop

20 & 21  
September  
2024

-  
Paris Brain  
Institute





## FRIDAY 20 SEPTEMBER 2024

### >> 9H: INTRODUCTION Jean-Yves Delattre (Paris)

### >> 9H15-9H30: 15 YEARS OF RESEARCH WITHIN THE POLA NETWORK, Caroline Dehais (Paris)

### >> 9H30-10H30: EXPERT PANEL DISCUSSION

**Neurosurgeons:** Fabien Rech (Nancy) and Florence Lefranc (Bruxelles)

**Biopathologists:** Dominique Figarella-Branger (Marseille), Kenneth Aldape (Bethesda) and Pim French (Rotterdam)

**Radiotherapists:** Loïc Feuvret (Lyon) and Jean-François Daisne (Louvain)

**Neurooncologists:** Andreas Höttinger (Lausanne) and Martin van den Bent (Rotterdam)

**Neuroradiologists:** Lucia Nichelli (Paris) and Julien Savatovsky (Paris)

**9H30:** Discussion of a case of low-grade oligodendroglioma: François Ducray (Lyon)

**10H:** Discussion of case of an anaplastic oligodendroglioma: Emeline Tabouret (Marseille)

### >> 10H30-10H45: ORAL ABSTRACT SESSION (TEASING POSTERS AND SELECTED ORAL COMMUNICATIONS)

### >> 10H45-11H15: COFFEE BREAK AND POSTER VIEWING

### >> 11H15-12H45: OLIGODENDROGLIOMA DIAGNOSIS AND CLASSIFICATION

**Karima Mokhtari (Paris) – Claude-Alain Muraige (Lille)**

**11h15-11h35:** Diagnosis of IDH-mutant 1p19q codeleted oligodendrogliomas: state of the art and challenges. Dominique Figarella-Branger (Marseille)

**11h35-11h55:** What can we expect from neuropathology 2.0 to predict prognosis and guide therapies? Kenneth Aldape (Bethesda)

**11h55-12h15:** What can be expected from liquid biopsies? Delphine Poncet (Lyon)

**12h15-12h30:** What have we learned from multi-omics analysis in oligodendrogliomas? François Ducray (Lyon)

**12h30-12h45:** How advanced imaging helps in the diagnosis and follow-up of oligodendrogliomas. Lucia Nichelli (Paris)

### >> 12H45-14H: LUNCH BREAK AND POSTER VIEWING

### >> 14H-16H: BIOLOGY OF OLIGODENDROGLIOMAS

**Keith Ligon (Boston) – Emmanuelle Uro Coste (Toulouse)**

**14h-14h20:** Molecular epidemiology of oligodendrogliomas. Marc Sanson (Paris)

**14h20-14h40:** What is oligodendrogliomas cell of origin? Jean-Philippe Hugnot (Montpellier)

**14h40-15h:** What do we know about oligodendrogliomas oncogenesis? Sevin Turcan (Heidelberg)

**15h-15h20:** What do we know about oligodendroglioma progression? Pim French (Rotterdam)

**15h20-15h40:** Neuro-glial interactions in oligodendrogliomas. Gilles Huberfeld (Paris)

**15h40-16h:** Oligodendrogliomas models: state of the art and perspectives. Emmanuelle Huillard (Paris)

### >> 16H-16H30: COFFEE BREAK AND POSTER VIEWING

### >> 16H30-18H10: TREATMENT OF OLIGODENDROGLIOMAS: STATE OF THE ART AND PERSPECTIVES

**Florence Lefranc (Bruxelles) – Jaime Gallego Perez de Larraya (Pampelune)**

**16h30-16h50:** Specificities of oligodendrogliomas surgery. Fabien Rech (Nancy)

**16h50-17h10:** When and how to treat oligodendrogliomas in the IDH inhibitor era? Martin van den Bent (Rotterdam)

**17h10-17h30:** Identifying therapeutic vulnerabilities in oligodendrogliomas. Sam McBrayer (Dallas)

**17h30-17h50:** Mechanisms and impact of hypermutation in oligodendrogliomas. Mehdi Touat (Paris)

**17h50-18h10:** Could oligodendrogliomas be candidate for IDH targeted vaccines? Michael Platten (Heidelberg)

**18h10-18h30:** Should oligodendrogliomas be treated with protontherapy? Loïc Feuvret (Lyon)



## SATURDAY 21 SEPTEMBER 2024

### >> 9H-10H: QUALITY OF LIFE AND COGNITIVE FUNCTIONING IN OLIGODENDROGLIOMAS

**Olivier Chinot (Marseille) – Brock Greene (San Francisco)**

**9h-9h20:** Long-term impact of treatment in oligodendrogliomas. Florian Boele (Leeds)

**9h20-9h40:** How to manage neurotoxicity in long-term oligodendroglial tumor survivors? Damien Ricard (Clamart)

**9h40-10h:** Epileptic seizures management in oligodendrogliomas. Roberta Ruda (Turin)

### >> 10-11H: SELECTED COMMUNICATIONS

### >> 11H-11H20: COFFEE BREAK AND POSTER VIEWING

### >> 11H20-12H50: HOW TO IMPROVE CARE AND RESEARCH IN OLIGODENDROGLIOMAS?

**Ahmed Idbah (Paris) – Kathy Oliver (Tadworth)**

**11h20-11h40:** Patients association perspective (1) Marie-Claude Berthy (Fonds Thomas Berthy / ARTC, France)

**11h40-12h:** Patients association perspective (2) Brock Greene (Oligo nation, USA)

**12h-12h20:** EURACAN network perspective. Jean-Yves Blay (Lyon, France)

**12h20-12h40:** EORTC perspective. Martin van den Bent (Rotterdam)

**12h40-12h50:** General discussion

### >> 12H50-13H: MEETING CONCLUSION



#### STEERING COMMITTEE

Catherine Carpentier (Paris), Caroline Dehais (Paris), François Ducray (Lyon), Dominique Figarella-Branger (Marseille), Emmanuelle Huillard (Paris), Armelle Lacroux (Paris), Sarah Levesque (Paris)

#### SCIENTIFIC COMMITTEE

Caroline Dehais (Paris), François Ducray (Lyon), Dominique Figarella-Branger (Marseille), Emmanuelle Huillard (Paris), Ahmed Idbah (Paris), Marc Sanson (Paris), Emeline Tabouret (Marseille), Mehdi Touat (Paris)

### >> CONTACT

Catherine Carpentier: [catherine.carpentier@icm-institute.org](mailto:catherine.carpentier@icm-institute.org)

With the support of

